PPARG and Obesity: Those with obesity have been reported to have greater glucose-lowering with thiazolidinediones (6, 7), which act to improve insulin sensitivity and lipid metabolism by stimulating the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARG).